Semaglutide, a newly available glucagon‐like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes-Reference-Cited by-同舟云学术

Semaglutide, a newly available glucagon‐like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes

Published:2021-04-19 Issue:1 Volume:26 Page:242-243
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Saito Suguru¹^ORCID,Nakao Toshiyuki²

Affiliation:

1. Department of Nephrology Tokyo Medical University Tokyo Japan

2. Organization for Kidney Metabolic Disease Treatment Tokyo Japan

Publisher

Wiley

Subject

Nephrology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.13651

Reference2 articles.

1. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

2. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide and Patients Receiving Hemodialysis: Case Reports of Unexpected Benefits for Hyperphosphatemia and Hyperkalemia;Canadian Journal of Hospital Pharmacy;2024-05-08

2. Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis;Nefrología (English Edition);2024-05

3. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis;Diseases;2024-01-02

4. Experiencia con dulaglutida en un paciente diabético y obeso en diálisis peritoneal incremental;Nefrología;2023-10

5. Vía de administración inusual de ciclosilicato de sodio y zirconio a través de sonda nasogástrica. A propósito de un caso;Nefrología;2023-08